Abstract 481P
Background
Identifying actionable driver mutations via tissue-based comprehensive genomic profiling (CGP) is paramount in treatment decisions for metastatic non-squamous, non-small cell lung cancer (NSCLC). Here, we elucidate the feasibility of CGP in early-stage NSCLC, and compare the tumor mutational burden (TMB) and mutation landscape using three different platforms.
Methods
Surgically resected NSCLC samples (N=96) collected between October 2011 and April 2020 at Yonsei Cancer Center were analyzed using whole-exome sequencing (WES) (Illumina DRAGEN, v3.8) (N=96), TruSight Oncology 500 (TSO500, v2.0) (for research use only) (Illumina) (N=96), and Foundation One CDx Assay (F1CDx) (N=26) to assess the concordance in TMB calculation and targetable mutations. Programmed death-ligand 1 (PD-L1) expression were evaluated using Vectra Polaris (Akoya).
Results
The stage distribution after surgery was 80% I (N=77) and 20% II (N=19). Ninety-nine percent (N=95) were adenocarcinoma. All 96 samples were analyzed with WES and TSO500. Among these samples, 26 samples were analyzed with F1CDx. The median TMB with WES and TSO500 was 1.57 and 4.7 mut/Mb, respectively (p<0.05). The median TMB was 1.88, 5.5, 4 mut/Mb for WES, TSO500 and F1CDx, respectively (p=0.0048). Linear regression analysis of TMB values calculated using concordance correlation coefficient (CCC) between WES and TSO500 resulted in a R2=0.76. For PD-L1 tumor proportion score (TPS) of <1% (negative, N=18), ≥1% (low, N=68) and ≥ 50% (high, N=10), the CCC were 0.075, 0.79, and 0.95, respectively. The CCC values for TMB concordance were variable between 3 platforms (WES vs. TSO500, R2=0.87; WES v. F1CDx, R2=0.72; TSO500 vs. F1CDx, R2=0.84). Mutation landscape revealed EGFR mutation (51%, N=49) as the most common actionable driver mutation, comprising of L858R (N=22), E19del (N=20), and other non-common EGFR mutations (N=7).
Conclusions
F1CDx and TSO500 showed robust analytical performance for TMB assessment with TSO500 showing stronger concordance of TMB with high PD-L1 expression. As paradigm for early-resected NSCLC continues to evolve, understanding TMB and mutation landscape may help advance clinical outcomes for this subset of patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Yonsei Cancer Center.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
203P - Neoadjuvant durvalumab plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC)
Presenter: Jia He
Session: Poster Display
Resources:
Abstract
204P - A radiomics strategy based on CT intra-tumoral and peritumoral regions for preoperative prediction of neoadjuvant chemoradiotherapy for esophageal cancer
Presenter: zhiyang li
Session: Poster Display
Resources:
Abstract
205TiP - IMPACT: Randomized, multicenter, phase III study evaluating the efficacy of immunotherapy (atezolizumab) plus anti-VEGF therapy (bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma (HCC)
Presenter: Tatsuya Yamashita
Session: Poster Display
Resources:
Abstract
206TiP - SIERRA: A phase IIIb, single-arm, multicentre study of tremelimumab plus durvalumab for first-line treatment of advanced unresectable hepatocellular carcinoma
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
207TiP - A two-arm randomized open-label prospective design superiority phase III clinical trial to compare the efficacy of docetaxel-oxaliplatin-capecitabine/ 5 -fluorouracil (DOC/F) followed by docetaxel versus CAPOX/mFOLFOX-7 in advanced gastric cancers
Presenter: Prabhat Bhargava
Session: Poster Display
Resources:
Abstract
212P - Mutational landscape and characteristics of ERBB2 in urothelial carcinoma
Presenter: Mingwei Li
Session: Poster Display
Resources:
Abstract
213P - Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma treated with first-line combination immunotherapies: Results from the International metastatic renal cell carcinoma database consortium (IMDC)
Presenter: Kosuke Takemura
Session: Poster Display
Resources:
Abstract
214P - Development and prospective validation of a multiplex RNA urine test for noninvasive detection and surveillance of urothelial carcinoma
Presenter: Hua Xu
Session: Poster Display
Resources:
Abstract
215P - Real-world outcomes of first-line tislelizumab plus axitinib in patients with metastatic non-clear cell renal cell carcinoma (mnccRCC)
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
216P - Preliminary efficacy and safety results from ‘ReBirth’: A phase II study of risk-based bladder-sparing therapy for MIBC
Presenter: Yijun Shen
Session: Poster Display
Resources:
Abstract